These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34154993)

  • 1. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of
    McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT
    Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
    Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
    J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs.
    Agarwal S; Allard R; Darcy J; Chigas S; Gu Y; Nguyen T; Bond S; Chong S; Wu JT; Janas MM
    Nucleic Acid Ther; 2021 Aug; 31(4):309-315. PubMed ID: 33861634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran.
    Ayyar VS; Song D
    J Pharm Sci; 2024 Jan; 113(1):176-190. PubMed ID: 37871778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved
    Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S
    Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of GalNAc-Conjugated siRNAs.
    An G
    J Clin Pharmacol; 2024 Jan; 64(1):45-57. PubMed ID: 37589246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview.
    Jeon JY; Ayyar VS; Mitra A
    Pharm Res; 2022 Aug; 39(8):1749-1759. PubMed ID: 35819583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters.
    Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S
    Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.
    Willoughby JLS; Chan A; Sehgal A; Butler JS; Nair JK; Racie T; Shulga-Morskaya S; Nguyen T; Qian K; Yucius K; Charisse K; van Berkel TJC; Manoharan M; Rajeev KG; Maier MA; Jadhav V; Zimmermann TS
    Mol Ther; 2018 Jan; 26(1):105-114. PubMed ID: 28988716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.
    Janas MM; Harbison CE; Perry VK; Carito B; Sutherland JE; Vaishnaw AK; Keirstead ND; Warner G
    Toxicol Pathol; 2018 Oct; 46(7):735-745. PubMed ID: 30139307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.
    Rajeev KG; Nair JK; Jayaraman M; Charisse K; Taneja N; O'Shea J; Willoughby JL; Yucius K; Nguyen T; Shulga-Morskaya S; Milstein S; Liebow A; Querbes W; Borodovsky A; Fitzgerald K; Maier MA; Manoharan M
    Chembiochem; 2015 Apr; 16(6):903-8. PubMed ID: 25786782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs).
    Sten S; Cardilin T; Antonsson M; Gennemark P
    Clin Pharmacokinet; 2023 Dec; 62(12):1661-1672. PubMed ID: 37824025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.
    Ranasinghe P; Addison ML; Dear JW; Webb DJ
    Br J Pharmacol; 2023 Nov; 180(21):2697-2720. PubMed ID: 36250252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.
    Springer AD; Dowdy SF
    Nucleic Acid Ther; 2018 Jun; 28(3):109-118. PubMed ID: 29792572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
    de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes.
    Matsuda S; Keiser K; Nair JK; Charisse K; Manoharan RM; Kretschmer P; Peng CG; V Kel'in A; Kandasamy P; Willoughby JL; Liebow A; Querbes W; Yucius K; Nguyen T; Milstein S; Maier MA; Rajeev KG; Manoharan M
    ACS Chem Biol; 2015 May; 10(5):1181-7. PubMed ID: 25730476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic Model.
    Lumen A; Zhang X; Dutta S; Upreti VV
    Clin Pharmacol Ther; 2024 May; 115(5):1054-1064. PubMed ID: 38282246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
    Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
    Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.
    Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J
    Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways.
    Kandasamy P; Mori S; Matsuda S; Erande N; Datta D; Willoughby JLS; Taneja N; O'Shea J; Bisbe A; Manoharan RM; Yucius K; Nguyen T; Indrakanti R; Gupta S; Gilbert JA; Racie T; Chan A; Liu J; Hutabarat R; Nair JK; Charisse K; Maier MA; Rajeev KG; Egli M; Manoharan M
    J Med Chem; 2023 Feb; 66(4):2506-2523. PubMed ID: 36757090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.